Trials / Completed
CompletedNCT01813630
A Clinical Study to Assess the Efficacy and Safety of DA-3002
Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Patients With Turner's Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- All
- Age
- 2 Years – 12 Years
- Healthy volunteers
- Not accepted
Summary
A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin®.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DA-3002 | |
| DRUG | Genotropin® |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2018-05-01
- Completion
- 2018-05-01
- First posted
- 2013-03-19
- Last updated
- 2018-07-26
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01813630. Inclusion in this directory is not an endorsement.